Loading company…
Singlomics is a Beijing-based company developing antibody-based drugs using a single-cell sequencing platform.
Established in 2020 and based in Beijing, China, Singlomics has 26 staff, with core scientists from Harvard University, Peking University, and Fudan University. It builds antibody-based drugs on a single-cell sequencing platform, with COVID-19 neutralizing antibodies DXP-593 and DXP-604, antibodies for chronic hepatitis B, and oncology candidates. It completed a Series A round of nearly $100 million from Chinese healthcare investors, and in 2022 it received CNY 300 million in Series B funding. CEO Dr. Qian Shi previously worked at Apollomics.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in